New approaches for the development and application of monoclonal antibodies for the diagnosis and therapy of human cancer.
Monoclonal antibodies (MAbs) represent potentially important reagents for both the diagnosis and therapy of human cancer. Innovative approaches are resulting in the improved production of MAbs and an enhanced ability to use these molecules therapeutically. Application of genetic engineering to MAb development is also resulting in the production of MAbs displaying enhanced target specificity. Of particular value for cancer therapy will be catalytic, bispecific, anti-idiotypic and human MAbs. By using agents that can augment the expression of tumor-associated antigens on cancer cells, a further increase in the utility of MAbs in cancer therapy will be forthcoming.